Evotopin
Withdrawn
This medicine's authorisation has been withdrawn
topotecan
MedicineHumanWithdrawn
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Evotopin has been withdrawn at the request of the marketing authorisation holder.
Product information
31/12/2009
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Evotopin
- Active substance
- topotecan
- International non-proprietary name (INN) or common name
- topotecan
- Therapeutic area (MeSH)
- Ovarian Neoplasms
- Anatomical therapeutic chemical (ATC) code
- L01CE01
Pharmacotherapeutic group
Antineoplastic agentsTherapeutic indication
Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.
This page was last updated on